https://www.blackhealth.org/articles/fda-auvelity-alzheimer-agitation-non-antipsychotic-black-dementia/Black Healthen2026-05-07T18:59:04.691472-05:00Auvelity is the first non-antipsychotic FDA approval for Alzheimer's agitation. The Black-dementia question is whether the underdiagnosis pattern in US Medicare data suppresses access to the new on-label option.